Editor: Samir A. Farghaly, MD, PhD,Scott M. Eisenkop, MD
Submission deadline: 31 December 2022
Editor: Michael Friedrich, MD,Nicolò Bertozzi, MD
Submission deadline: 30 April 2022
Editor: Enrique Hernandez, MD
Submission deadline: 25 April 2022
Editor: Ottavia Dʼoria, MD
Submission deadline: 31 October 2023
Editor: Prof. Takuma Hayashi
Submission deadline: 31 October 2023
Editor: Liaqat Ali, PhD
Submission deadline: 31 October 2022
Editor: Masuma Khatun, PhD
Submission deadline: 24 June 2023
Editor: Nicolae Gica, MD, PhD,Yoland Antill, BMed FRACP MD
Submission deadline: 31 July 2023
8.Publishing Standards and Report Guidelines
A summary of the editorial process is given in the flowchart below.
European Journal of Gynaecological Oncology Editorial Process
The following provides notes on each step.
Immediately after submission, a Preliminary review will first be carried out by the managing editor to assess if the submitted manuscript complies with the provided guidelines for preparation of articles. Articles that do not comply with the guidelines will be sent back to the authors. The relevant editor (usually the Editor-in-Chief/Editorial Board Member of a journal or the Guest Editor of a Special Issue) will then be notified of the submission and invited to perform a Pre-check. The relevant editors can decide to continue with the peer-review process, reject a manuscript, or request revisions before peer-review.
European Journal of Gynaecological Oncology requires that editorial staff or editors not be involved in processing their own academic work. The Editor or members of the Editorial Board may occasionally submit their own manuscripts for possible publication in the journal. In these cases, the peer review process will be managed by alternative members of the Board. Submissions will be assigned to at least two independent outside reviewers. The submitting Editor/Board member will have no involvement in the decision-making process. Decisions will be made by other Editorial Board Members who do not have a conflict of interest with the author.
Guest Editors should not hold conflicts of interest with authors whose work they are assessing (e.g., from the same institution or collaborate closely). In this case, the Editor-in-Chief or a suitable Editorial Board member will make the Pre-check and Final decisions for submitted papers.
European Journal of Gynaecological Oncology adopts double-blind peer review. Once a manuscript passes the initial checks, it will be assigned to at least two independent experts for peer-review. EJGO editors will check to make sure there are no conflicts of interest before contacting reviewers, and will not consider those with competing interests. Reviewers are asked to declare any conflicts of interest before reviewing any submitted manuscript.
In cases Minor revisions/Major revisions are recommended, the author is usually requested to revise the paper before referring to the relevant editor (usually the Editor-in-Chief/Editorial Board Member of a journal or the Guest Editor of a Special Issue). Articles may or may not be sent to reviewers after minor revision, which depends on whether the reviewer requested to see the revised version or not. The revised manuscript after major revision will be sent back to reviewers again. We typically allow no more than two rounds of major revisions per manuscript. Any further revision needed will follow the decision of the relevant editors.
All reviewer comments should be responded point-by-point. Where the authors disagree with a reviewer, they must provide a clear response or rebuttal.
The acceptance of the manuscript will depend on the revisions made to the manuscript. Authors need to provide a point by point response or a rebuttal if some of the reviewer’s comments cannot be revised. The Acceptance or rejection decision will be made by the relevant editor (usually the Editor-in-Chief/Editorial Board Member of a journal or the Guest Editor of a Special Issue) after peer review, and the editor can select from the following options: Accept in Present Form, Accept after Minor Revisions, Reconsider after Major Revisions, Reject.
Authors may appeal a rejection judgement by sending an e-mail to the journal’s Editorial Office. The appeal must provide a detailed justification, including point-by-point responses to the reviewers' and/or Editor's comments. The Managing Editor of the journal will forward the manuscript and related information (including the identities of the referees) to the Editor-in-Chief, Associate Editor, or Editorial Board member. The Editor being consulted will subsequently be asked to provide an advisory recommendation on the manuscript and may recommend acceptance, further peer-review, or uphold the original rejection decision. A reject decision at this stage is final and cannot be reversed.
EJGO carries out production on all manuscripts, including copy editing, layout and conversion to XML. Language editing is carried out by professional English editing editors. We recommend authors use Englishgo’s English editing service prior to publication or during revisions. If you have used an alternative service, please provide a copy certificate to the Editorial Office.
The submitted, accepted and published dates will be shown in the PDF and XML files of the published articles, a digital object identifier (DOI) number will also be assigned for each published article. The submitted date is the date on which the editors received the original (or if previously rejected, the resubmitted) manuscript. The accepted date is when the editor sends the acceptance letter. The published date is the earliest date that the final version-of-record is made available on the publisher's website.
EJGO follows the following guidelines and standards. Submission of a manuscript to European Journal of Gynaecological Oncology implies that all authors have read and agreed to its content, and the manuscript conforms to the journal’s policies.
ICMJE: Medically related EJGO follows the recommendations of the International Committee of Medical Journal Editors. The guidelines comprehensively cover all aspects of editing, from how the journal is managed to details about peer review and handling complaints.
CONSORT statement covers reporting of randomized, controlled trials. We encourage authors to verify their work against the checklist and flow diagram and upload them with their submission.
PRISMA covers systematic reviews and meta-analyses of interventional studies and MOOSE for systematic reviews and meta-analyses of observational studies. Authors are recommended to complete the checklist and flow diagram and include them with their submission.
ARRIVE contains guidelines for reporting in vivo experiments. Authors are recommended to verify their work against the checklist and include it with their submission.
STROBE guidelines cover reporting of observational studies. Also, for diagnostic studies, authors are encouraged to use STARD guideline.
CARE guideline (for CAse REports) was developed by an international group of experts to support an increase in the accuracy, transparency, and usefulness of case reports. View and download the CARE checklist.
Other related guidelines, please visit the equator network (https://www.equator-network.org/).
EJGO follows the guidelines of the Committee on Publication Ethics (COPE) and the International Committee of Medical Journal Editors (ICMJE) Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals.
EJGO follows COPE’s procedures for dealing with potentially unethical behavior by authors, reviewers or editors. Our editorial staff are trained in how to detect and respond to potential ethical problems.
More information about our Publishing Ethics policy.
Editorial independence dictates that decision to accept or reject a manuscript is based on the scientific merit of the article but not to any other relations for example pressure from the publisher to the journal editor. This means that Editor is independent in his/her decision and will not be under pressure of any influential body or organization.
Our editorial policy is consistent with the principles of editorial independence presented by the World Association of Medical Editors (WAME).
Vol., Issue , Invalid dateTable of contents
Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.
Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.
Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.
JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.
Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.
BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.
Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.